Aprea Accelerates WEE1 Inhibitor Trial, Plans Q4 Data Readout
APRE is trading near its 52-week low of $0.548 (15% above the low).
Summary
Aprea is significantly expanding its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor APR-1051, tripling active sites from 3 to 10 and targeting enrollment of 6–10 patients per month by Q4 2026. The company plans to add combination arms in HPV+ head and neck cancer (with immunotherapy) and colorectal cancer (with chemotherapy), building on preclinical synergy data. A clinical data update is now planned for a Q4 2026 medical meeting, providing a near-term catalyst. This follows positive single-agent activity and tolerability shown at ASCO 2026, and the expansion into biomarker-defined populations like uterine serous carcinoma and cyclin E-overexpressing ovarian cancer sharpens the drug's precision oncology focus. With a cash runway into Q1 2028, the company has resources to execute this broader development plan.
At the time of this announcement, APRE was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $0.55 to $1.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.